Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations

Maurizio Salvadori, Elisabetta Bertoni

Maurizio Salvadori, Elisabetta Bertoni, Renal Unit, Careggi Hospital, Careggi University, Florence 50139, Italy

Author contributions: Salvadori M and Bertoni E equally contributed to writing the paper, collecting the literature data, revising both the scientific contents and the English wording, and gave the final approval of the version to be published.

Correspondence to: Maurizio Salvadori, MD, Professor, Renal Unit, Careggi Hospital, Careggi University, Viale Pieraccini 18, Florence 50139, Italy. maurizio.salvadori1@gmail.com

Telephone: +39-55-7949269 Fax: +39-55-435878

Received: May 7, 2013 Revised: June 26, 2013
Accepted: August 2, 2013 Published online: August 6, 2013

Abstract

Hemolytic uremic syndrome (HUS) is a rare disease. In this work the authors review the recent findings on HUS, considering the different etiologic and pathogenetic classifications. New findings in genetics and, in particular, mutations of genes that encode the complement-regulatory proteins have improved our understanding of atypical HUS. Similarly, the complement proteins are clearly involved in all types of thrombotic microangiopathy: typical HUS, atypical HUS and thrombotic thrombocytopenic purpura (TTP). Furthermore, several secondary HUS appear to be related to abnormalities in complement genes in predisposed patients. The authors highlight the therapeutic aspects of this rare disease, examining both "traditional therapy" (including plasma therapy, kidney and kidney-liver transplantation) and "new therapies". The latter include anti-Shiga-toxin antibodies and anti-C5 monoclonal antibody "eculizumab". Eculizumab has been recently launched for the treatment of the atypical HUS, but it appears to be effective in the treatment of typical HUS and in TTP. Future therapies are in phases I and II. They include anti-C5 antibodies, which are more purified, less immunogenic and absorbed orally and, anti-C3 antibodies, which are more powerful, but potentially less safe. Additionally, infusions of recombinant complement-regulatory proteins are a potential future therapy.

© 2013 Baishideng. All rights reserved.

Key words: Enterohemorrhagic Escherichia coli; Diarrhea, Shiga toxin (Stx) 1 and Stx 2; Atypical hemolytic uremic syndrome; Complement factors; Thrombotic thrombocytopenic purpura; Secondary thrombotic microangiopathy; Plasma therapy; Eculizumab

Core tip: Hemolytic uremic syndrome (HUS) is a rare disease, knowledge of which is rapidly increasing. The disease takes several forms, but recent data suggest that the physiopathologic basis in the vast majority of such diseases is complement dysregulation. New therapies are available, including a monoclonal antibody that blocks the C5 cascade. Such therapies lead to a substantial improvement in the outcome, which previously was often poor. HUS often occurs secondary to other diseases. In such cases, diagnosis may be difficult due to the overlapping of two diseases. Complement dysregulation has been found also in secondary HUS.

Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol 2013; 2(3): 56-76 Available from: URL: http://www.wjgnet.com/2220-6124/full/v2/i3/56.htm DOI: http://dx.doi.org/10.5527/wjn.v2.i3.56

DEFINITION AND ETIOLOGY

Hemolytic uremic syndrome (HUS) was first described in 1955 by Gasser et al[1]. HUS is a thrombotic microangiopathy that is characterized by three primary symptoms: hemolytic anemia with fragmentocytes, low platelet count and acute renal failure. HUS is a heterogeneous group of hemolytic disorders and thrombotic microangiopathies
ETIOLOGICAL CLASSIFICATION OF HUS

HUS is classified into three primary types: (1) HUS due to infections, often associated with diarrhea (D+HUS), with the rare exception of HUS due to a severe disseminated infection caused by *Streptococcus*; (2) HUS related to complement abnormalities or related to factor-ADAMTS13 deficit, such HUS is also known as “atypical HUS” and is not diarrhea associated (D-HUS); and (3) HUS of unknown etiology that usually occurs in the course of systemic diseases or physiopathologic conditions such as pregnancy, after transplantation of drug assumption.

Overlapping HUSs occur when two or more of the above-mentioned conditions coexist in the same patient.

Infectious HUS

Infectious HUS, diarrhea associated. Frequently, this form follows an enteric disease caused by Shiga toxin-producing *Escherichia coli* (E. coli) or *Shigella dysenteriae*. Shiga toxin-related HUS is the most common cause of acute renal failure in childhood and constitutes 90% of all HUS cases in this population.[4]

Gasser *et al*.[1] was the first to characterize HUS describing 5 patients who died with hemolytic anemia, acute renal failure and low platelet counts. Thirty years later Karmali *et al*.[3] found the cause of the disease; all patients with HUS D+ had an *E. coli* strain in their feces that produced a toxin that caused irreversible damage to Vero cells in vitro. Later, this toxin was found to be similar to the Shiga toxin produced by type 1 *Shigella dysenteriae*.[4]

**Epidemiology**

Infections caused by Shiga toxin-producing *E. coli* serotype O157:H7 are the most common cause of HUS in North America, west Europe, Japan, South America, Africa and Australia.[7,8] HUS D+ is more often sporadic, but large outbreaks have been reported. Cattle and sheep are the main reservoirs, and the major transmission route is believed to be food contaminated with animal feces.[8-18]

Contaminated water has also been recognized as a source,[19] and direct human-to-human and animal-to-human transmission have been reported.[20] *E. coli* O104:H4 recently caused a large outbreak in 4000 HUS D+ patients, with 50 deaths in Germany and 15 other countries.[21]

The incidence rate of HUS D+ differs according to countries and climate and is higher in colder countries. For example, the incidence rate in Scotland (3.4 × 10^5 children under age 5) is higher than the overall incidence rate in Great Britain (1.54 × 10^5 children under age 5).[22] England and France have similar incidence rates, both of which are higher than that in Italy.[21]

The HUS D+ incidence rate is highest in children aged one-to-five years in Europe and North America, while, the incidence rate in Argentina is higher in younger children (6 mo to four years).[20]

**Microbiology**

*E. coli* O157:H7 is the most commonly involved serotype; recently, other serotypes have also been described. Gerber *et al*.[23] in a prospective study described 394 pediatric patients with HUS. They found that 43% of these children had an *E. coli* strain other than O157:H7 in their stool: O26: H11/H- (15%), O157:H- (10%), O145: 28/H- (9%), O103/H2/H- (3%) and O111/H8/H (3%). *E. coli* is the most commonly involved species, *Shigella Dysenteriae* type I and *Citrobacter freundii* have less frequently observed.[20]

**Pathophysiology**

After an *E. coli* infection with production of Shiga-toxin, several factors influence the progression of the disease to HUS. (1) Bacterial strain. For serotype O157:H7, the progression is approximately 15%/27; (2) Age: In children younger than 5 years, the rate of progression is 12.9%, while it is 6.8% in children between 5 and 10-year-old and 8% in children over 10 years[28]; (3) Antibiotic therapy. Antibiotic therapy for *E. coli* O157/H7 infection

---

**Table 1** Etiology of Hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and related disorders

| Etiology identified | Etiology unknown |
|--------------------|------------------|
| HUS infection-induced | HIV infection |
| (1) Shiga and shiga-like toxin producing bacteria, *Enteroheamorrhagic Escherichia coli*, Shigella dysenteriae type 1 | |
| (2) Streptococcus pneumoniae | |
| HUS induced by disorders of complement regulation | Malignancy, cancer chemotherapy, ionizing radiation |
| (1) Genetic | |
| (2) Acquired | |
| ADAMTS13 deficiency | |
| (1) Genetic | |
| (2) Acquired | |
| Defective cobalamin metabolism | |
| Hernia | |

HIV: human immunodeficiency virus; HELLP: Hemolysis elevated liver enzymes low platelets; HUS: Hemolytic uremic syndrome.

*Salvadori M et al.* Hemolytic uremic syndrome: An update
Salvadori M et al. Hemolytic uremic syndrome: An update

Table 2  Development of Shiga-toxin-associated hemolytic uremic syndrome

| Pathogenetic steps | Clinical |
|--------------------|----------|
| Ingestion of *Escherichia Coli* through contaminated food or patient to patient transmission or transmission from animal to man | Colonization of the gut |
| Diarrhea | Local tissue damage |
| Bloody diarrhea | Systemic toxemia |
| Generation of host cytokines and chemokines | Endothelial cell damage, activation of local thrombosis in kidneys and in other organs |
| Renal involvement→ HUS | Damage to glomerular endothelial cells, arteriolar damage, mesangial cell activation/damage, podocyte injury, tubular damage |
| Renal Insufficiency | Acute renal failure |
| | Chronic renal failure |
| | Arterial hypertension, proteinuria, hematuria |

HUS: Hemolytic uremic syndrome.

**INFECTIOUS HUS NOT DIARRHEA ASSOCIATED**

*Streptococcus pneumoniae* may cause a rare and severe infectious form of HUS, without diarrhea (SPA-HUS) [43].

**Pathophysiology**

Cellular injury is thought to be related to exposure of the normally hidden Thomsen Friedenreich T-antigen. *Streptococcus Pneumoniae* produces a circulating neuraminidase that removes N-acetylneuraminic acid from cell surfaces. As a consequence, the normally circulating T-antigen antibodies react with the newly exposed T-antigen on red blood cells, platelets and endothelial cells, thus causing hemolytic anemia, thrombocytopenia and micro vascular injury [42].

**Clinical features**

This streptococcal infection is generally severe, disseminated, associated with septicemia, meningitis and pneumonia complicated by empyema. A Canadian study compared children with D+HUS to children with SPA-HUS. The latter were younger; more often had severe renal or hematological diseases, and more often required dialysis [43]. SPA-HUS mortality is high (30%-50%) and patients who recover commonly experience renal failure due to cortical necrosis.

**Differential diagnosis**

Figure 2 represents a diagnostic algorithm to distinguish among the different forms of HUS. In subjects previously with diarrhea and who are older than 6 mo, the diagnosis of HUS syndrome due to Shiga toxin should be strongly considered, especially if the episode occurs in

may increase the risk of HUS [30], though a recent meta-analysis does not confirm this association [39], and (4) Environmental and genetic factors. Such factors are not yet fully understood, but several authors have suggested that factor-H abnormalities could influence the disease evolution in HUS D+ [39]. Shiga toxin is produced by *E. coli* in the gut and is then absorbed [31].

Shiga toxin consists of two subunits: A and B. Subunit A, approximately 32 kDa, is cleaved by proteolysis into two peptides: A1 (28 kDa) and A2 (4 kDa). In target organs (e.g., kidney, brain and gut), subunit B recognize and binds to glycolipid receptors on the cell surface. In humans this receptor is Gb3 (globotriosilceramyde) and is highly expressed on kidney tubular cells, and brain and gut endothelial cells. Moreover, in the kidney cytotoxicity is further amplified by tumor necrosis factor-α (TNF-α) [32,33].

After binding to cell surfaces, Shiga toxin is endocytosed and retrograde-transported to the Golgi apparatus and the endoplasmic reticulum; it is then translocated to the cytosol where it inactivates ribosomes and causes cell death [34]. The pathogenetic mechanisms are shown in Figure 1.

**Clinical features**

After 3-8 d of incubation, the first symptom is watery diarrhea, followed by bloody diarrhea and abdominal cramps. Nausea and vomiting are also present. Fever is less commonly observed. The most important factors associated with HUS evolution are the use of anti-motility agents, antibiotics, bloody diarrhea, leukocytosis, young age and female gender. The risk of developing HUS after bloody diarrhea due to *E. coli* is approximately 15% [35]. Recovery is often spontaneous, but 26% of patients develop renal failure, with 3%-5% of deaths [36,37].

Hematological and renal symptoms, including hemolytic anemia, low platelet counts, fragmentocytes, increased lactate dehydrogenase (LDH) and very low apotoglobin levels and various degrees of renal failure may all be present. Other symptoms may arise due to the involvement of other organs such as the brain, pancreas and myocardium [38-40]. Malignant hypertension, when present, is associated with kidney failure and central nervous system involvement. The main clinical and pathoge-
an endemic area and is not associated with pneumococcal infection. When HUS episode co-occurs with invasive pneumococcal infection, HUS due to pneumococcus should be suspected, even in presence of diarrhea.

As mentioned above, overlapping HUSs are commonly observed, and any HUS may lack some typical clinical symptoms. For example, Shiga-toxin related HUSs may occur without diarrhea, and HUSs related to complement abnormalities are commonly observed in the presence of diarrhea. Differential diagnosis may be difficult. In patients with HUS D+ with insidious onset, tendency to relapse and a familiar presentation, all complement abnormalities should be tested for, with particular attention to overlap syndrome.

**DIAGNOSTIC RECOMMENDATION FOR INFECTIOUS HUS**

All patients with enterohemorrhagic diarrhea, especially in endemic or epidemic areas for *E. coli* should be admitted in specialized units.

Epidemiological and familial histories should be taken. Stools should be collected promptly and tested specifically for *E. coli* O157:H7 with culture, Polymerase Chain Reaction (PCR), serology and anti-O157-antibody titer in serum. PCR and testing for anti-LPS antibodies of prevalent serotypes should be conducted.

All patients with relapsing diarrhea associated HUS, with the presence of a family history of the syndrome in their family or with insidious onset should be screened for complement proteins and ADAMTS13 protease. When Pneumococcus infection is suspected, a bacterial culture of sterile body fluids should be conducted.

**HUS RELATED TO COMPLEMENT ABNORMALITIES OR TO FACTOR ADAMTS13 DEFICIT: “ATYPICAL HUS”**

According several physicians “typical HUS” is the syndrome above described while all other forms should be called “atypical HUS” (aHUS). As aforementioned in this paper we follow the classification proposed by the European Study Group for HUS and related syndromes.[2]

aHUS is more properly linked to complement abnormalities, although several authors discuss it alongside thrombotic thrombocytopenic purpura (TTP). aHUS and TTP share a common pathologic lesion (thrombotic microangiopathy) but have different clinical manifestations. In aHUS the lesions and clinical symptoms are primarily localized in the kidney, whereas the pathologic changes of TTP are more extensively distributed, most likely reflecting the systemic nature of the underlying defect. Clinically, TTP occurs more often with central-nervous-system symptoms, but renal insufficiency has also been reported.

**Atypical HUS due to complement abnormalities**

aHUS is less common than typical HUS and is characterized by a worse outcome. The disease may have a familial or a sporadic pattern and, may arise due to genetic abnormalities or be acquired[34].

**Epidemiology**

The incidence of aHUS in The United States of America...
ica is approximately two per million\textsuperscript{[45]}. In Europe, five national and continental registries report more than 1000 patients with complement abnormalities with an incidence of approximately 1.5-1.8 per million inhabitants\textsuperscript{[46,47]}. Overall, aHUS accounts for 5% of all HUS cases. Atypical HUS may develop in patients of any age, though 70% of pediatric diseases have an onset before two years and 25% have an onset before the age of 6 mo\textsuperscript{[48]}. HUS occurring before 6 mo of age is suggestive of aHUS because less than 5% of D+HUS cases occur before the age of 6 mo.

Pathophysiology

An infection, usually of the respiratory tract, or an episode of diarrhea, triggers the onset of aHUS in 50% of adult forms and 80% of pediatric forms\textsuperscript{[49]}. This pattern highlights the difficulty in distinguishing HUS D+ from HUS D-. In addition, as mentioned above, HUS onset after an episode of diarrhea does not rule out atypical HUS. Additionally, several physiopathologic conditions, such as pregnancy may trigger atypical HUS; 20% of such diseases develop during pregnancy and 80% develop after delivery\textsuperscript{[50,51]}.

COMPLEMENT SYSTEM AND DYSREGULATION

The clear link between atypical HUS and the complement pathway is well recognized. In the last ten years several mutations in genes encoding complement proteins have been identified in patients presenting with atypical HUS. Atypical HUS is an ultra-rare kidney disease and manifests as a microangiopathy disease with mechanic anemia, thrombocytopenia and acute renal failure. Mutations have been identified in factor H, MCP, factor I and thrombomodulin (THBD). These proteins act as regulating factors of the C3 convertase. Additional mutations have been identified in C3 and factor B. Anti-factor H antibodies have been identified in patients with atypical HUS, particularly in children. Anti-factor I antibodies have also recently been identified. Overall, up to 100000 individuals from cohorts in Europe and the United States have been screened for genetic abnormalities.

The complement cascade may be activated by three pathways: the classical, lectin and alternative pathways. The alternative pathway is constitutively active in plasma and leads to a minor attack on all structures in contact with the plasma and other body fluids. Under normal conditions this attack is rapidly down-regulated and there is no damage to cells. The alternative pathway must be strictly regulated to attack only foreign cells by a set of regulatory proteins in plasma and on the host cell membranes.

The alternative pathway (Figure 3) is continuously activated by the spontaneous hydrolysis of C3, the so-called tick-over. C3 activation generates the anaphylatoxin C3a and the fragment C3b, which binds to factor B, which in turn is cleaved by factor D to Bb. Consequently the C3 convertase C3bBbP is formed. This complex generates more C3b through an amplification loop. C3BbP is relatively labile and undergoes spontaneous decay through the dissociation of Bb. Properdin, synthesized by monocytes and T lymphocytes, binds to and stabilizes C3bBbP, thus preventing its decay. As the process continues more C3b is formed and deposited on the cell surface. Thus (C3b): BbP is formed and acts as the C5 convertase that cleaves C5. C5b activates the terminal complement pathway by associating with C6, C7, and C8 to form macro-molecular complexes called C5b-8, which can bind to cell membranes. C9 binds to this complex, forming C5b-9, the membrane-attack complex (MAC). MAC is responsible for (primarily endothelial) cell damage and favors microthrombosis.

Several different regulatory proteins, that disrupt complement activation process, are present under normal conditions to prevent complement activation on the host cell (Figure 4). Complement Receptor 1 (CR1 or CD35) and decay-accelerating factor (DAF or CD55) compete with factor B in binding with C3b on the cell surface and can remove Bb from a C3bBb complex\textsuperscript{[52]}. The formation of a C3 convertase may also be prevented when a plasma protease called factor I\textsuperscript{[53]} cleaves C3b into its inactive form, iC3b. Factor I requires a C3b-binding protein cofactor such as complement factors H, CR1, membrane cofactor protein (MCP or CD46) or thrombomodulin\textsuperscript{[54,56]}. Additionally, the plasma protease factor H may inhibit the formation of the C3 convertase.
by competing with factor B for binding to C3b.

CFHR5 (Complement Factor-H related protein 5) is able to bind to and act as a cofactor for Factor I, has decay accelerating activity and is able to bind preferentially to C3b on the host cell surface.

Factor H is a highly glycosylated protein of 155 kDa. Factor H is composed of 20 repetitive modules of approximately about 60 amino acids, the Short Consensus Repeat (SCR) which forms a flexible structure. The sites of interaction between FH and its different ligands are well known. Two sites are involved in C3b binding (SCR 1-4 and SCR 19-20). The SCR 7, 19-20 bind to the protein molecules on the cell surface.

Factor H has different effects on the complement cascade. Factor H blocks C3 convertase and favors its degradation. Factor H can act also as a factor I co-factor causing C3b proteolysis and generating the inactivated C3b (iC3b). Moreover, factor H may bind to molecules on the cell surface and act as inhibitors. membrane co-factor protein (MCP/CD46) is located only on the cell surface where it acts as a co-factor for factor I. MCP/CD46 is a transmembrane glycoprotein that is highly expressed on the surfaces of all cells, with the exception of erythrocytes. The extra-membrane portion of the molecule is formed of 4 SCR domains. The SCR 2, 3 and 4 bind to C3b and act as the co-factor for factor I.

Factor I is 88-kDa glycoprotein that belongs to the serine protease family. It cleaves the alpha chain of C3b, generating an inactive fragment (iC3b) that is unable to generate C3 convertase.

THBD has recently been demonstrated to down-regulate the alternative complement pathway by accelerating the factor I-mediated inactivation of C3b in the presence of co-factors.

Typical HUS D+ is well known, but new discoveries are continuatively being made on the role of complement alterations in the pathogenesis of atypical HUS, especially over the last decade.

**GENETIC BASIS OF aHUS**

The relationship between low plasma C3 and HUS was first described by Cameron in 1973. The association between HUS and low factor H levels had been described by the 1980s. In 1998, Warwicker described for the first time a mutation in the gene encoding factor H in cases of familial HUS.

Since then, more than 100 mutations of factor H have been identified in adults or children with HUS. Several mutations are associated with quantitative deficit of factor H (type 1 mutations); others are associated with factor H normal levels (type 2 mutations). MCP mutations were first described by Richards in 2003. The factor I mutation was first described in 2004. To date, more than ten mutations in factor I have been identified. In 2008, Goicoechea de Jorge described a gain of function mutation encoding a complement activator in factor B, thus creating a “super factor B”.

**Factor-H mutations**

The association between atypical HUS and low serum levels of factor H was described 30 years ago. To date, more than 70 genetic abnormalities have been identified throughout the gene. The mutations are of all types: nonsense, missense, small deletion/insertion. Several patients had homozygous mutations but most patients were heterozygous. Mutations may be classified into two groups. Patients presenting quantitative factor H deficiency have a type I mutation. Such patients have low levels of factor H, which is associated with an uncontrolled activation of the fluid phase, corresponding to a low C3 level in plasma. The second group of patients has type II mutations: they have a functional deficiency of factor H, though the levels of factor H and C3 are often in the normal range. Homozygous mutations are associated with very low plasma C3 and factor H. Factor H mutations are the most common in atypical HUS and are found in 20%-30% of these patients.

**Anti factor H antibodies**

An acquired factor H dysfunction is associated with anti-factor H auto antibodies. IgG anti-factor H binds to factor H and inhibits its binding to C3b and to the cell surface. Low C3 levels are observed in 40%-60% of patients with anti-factor H antibodies, according to the IgG circulating titer. Moore et al. reported an association of factor H auto-antibodies with mutations of CFH, CFI, MCP and C3 in 13 patients with aHUS. Anti-factor H antibodies are responsible for 6% of the aHUS cases among the general population, and are more common in children.

**MCP mutations**

More than 40 mutations of MCP have been identified, since the first report ten years ago. The mutant MCP binds C3b weakly and has no activity as a co-factor. Mutations are most commonly located between the EXON 1 and EXON 6. Homozygous mutations with complete CD46 deficiency and heterozygous mutations associated with a partial deficiency have been identified. The vast majority of patients have low MCP on peripheral leukocytes: this is a useful diagnostic tool. The C3 levels in patients with MCP mutations are usually normal. MCP mutations account for 5%-15% of aHUS cases and are more common in children than in adults. When MCP mutation is associated with low C3 levels, other mutations of complement factors may also be associated.

**Factor I mutations**

Approximately 40 different factor I mutations have been identified in patients with aHUS. All of the identified mutations were heterozygous. Factor I mutations may cause either a defect in protein secretion or a modification of the protein structure, with a consequent reduction in its co-factorial activity. Therefore, the reduced degradation of C3b/C4b is observed either in the fluid.
Salvadori M et al. Hemolytic uremic syndrome: An update

Table 3 Gene mutation rate of different complement factors according to hemolytic uremic syndrome registries data

| Abnormality         | Gene locus     | Atypical HUS rate |
|---------------------|----------------|-------------------|
| Factor H            | CFH (RCA:q32)  | 11%-29%           |
| Membrane co-factor  | MCP (RCA)      | 3%-17%            |
| Protein             | Factor I       | 4q25              |
| C3                  | CFI            | 19p13             |
| Factor B            | CFB            | 6p21              |
| Thrombomodulin      | THBD           | 20p11             |
| Anti factor H autoantibodies |             | 4%-13%            |

HUS: Hemolytic uremic syndrome.

phase or on the cell surface. The frequency of factor I mutations in patients with aHUS ranges from 4% to 10%. 30% of patients with factor I mutations also have mutations in other genes encoding complement-regulatory proteins[66]. Recent molecular studies demonstrated four novel mutations in a cohort of screened individuals; among them, the first major gene deletion in the CFI locus was described[76].

**THBD mutations**

Heterozygous mutations in the THBD gene were recently documented in Italy[67,68]. Cells with anomalous THBD are less efficient at inactivating C3b. THBD mutations account for 3%-5% of patients with aHUS, according to registries from United States[77] and Italy[67]. In addition, mutations related to the genes encoding proteins that activate and potentiate the complement pathway may occur. Such mutations determine a “gain of function”.

**Complement factor B mutations and C3 mutations**

To date, few heterozygous CFB mutations have been described in patients with aHUS[66,68]. These mutations result in increased stability and activity for C3 convertase due to a “super B factor”. These patients have a continuously activated alternative pathway, with very low C3 levels. These mutations are rare, accounting for 1%-4% of patients with aHUS[67]. In 25% of patients a functional consequence of the mutation has been identified. Only four mutations in factor B have been functionally characterized. All of these mutations are located in the vWF domain of the proteins, where C3 and factor B bind. All mutations are heterozygous and associated with C3 consumption. Therefore there are two functional consequences: (1) A direct gain of function mutation leads to excess binding and affinity between factor B and C3b; and (2) There is also an indirect gain-of-function mutation; indeed there is a reduction in C3b binding to factor H and MCP. Thus, in both cases that yield a super C3 convertase, it is more efficient to cleave the C3 on the cells.

Heterozygous C3 mutations have also been described[67]. Such C3 binds weakly to MCP, indirectly causing a gain of function. Consequently, there is an increased binding of CFB to C3b and an increase in C3 convertase. 2%-10% of patients with aHUS have C3 mutation[77]. The defect caused by these mutations is a proteolytic inactiva-

tion of C3b, but it is difficult to delete C3 and form iC3b on the cells. 28 mutations in C3 have been identified; most are heterozygous and are associated with induced C3 consumption and low serum C3. Table 3 reports the frequencies of various mutations in complement-factors genes according to registry data.

**Combined mutations**

Up to 12% of patients with aHUS have two or more mutations in CFH, CFI, MCP, THBD, CFB and CFH[81]. In conclusion, one or more abnormalities in the regulatory complement system have been documented in 70% of pediatric or adult patients with aHUS. In contrast to date in 30% of aHUS no abnormality has been found[82].

**INCOMPLETE PENETRANCE OF aHUS**

Mutations in complement-regulating genes can be found in healthy family members: the penetrance of the disease among carriers of mutations in CFH, CFI and MCP is approximately 50%-60%[66,67]. Thus, the genetic aberrations are important but are not sufficient for the development of aHUS. Affected patients may carry multiple mutations, in more than one gene[67,83] or a mutation in combination with the associated CFH or MCP haplotype. Family members who only carry one mutation or no polymorphisms are not affected, but this could be due to incomplete penetrance. Atypical HUS may not occur until adulthood, even in patients with multiple genetic defects. Thus, an environmental factor, acting as a complement trigger, is most likely essential to developing the disease. In patients with a mutation in CFH, CFI or MCP, the clinical symptoms are commonly preceded by flu-like symptoms, gastroenteritis or other infections[67].

In conclusion, atypical HUS requires both environmental factors and genetic abnormalities. In addition to the abnormalities already described, at least two polymorphisms in CFH and MCP modulate the presence and severity of the disease. These observations, along with the finding that approximately 10% of patients with aHUS have mutations in more than one complement gene, indicate that the coincidence of different genetic risk factors is a determining factor in the development of aHUS (multiple hits theory)[84,85]. Indeed, aHUS is a complex disease that normally involves the combination of multiple genetic and environmental risk factors. Commonly, patients will have more than one mutation in the genes encoding complement factors, or a combination of mutations with risk-associated polymorphisms. This explains the incomplete penetrance of aHUS, and the differences in its presentation and progression.

**Diagnosis**

Screening for complement-system abnormalities: Determination of serum C3 and C4 levels constitutes the base of complement screening. In almost all cases of aHUS C4 levels are normal. Low C3 levels are commonly observed in patients with mutations in CFH, CFI and MCP[68]. Nev-
ertheless normal C3 levels do not exclude the presence of mutations in complement-regulatory proteins\textsuperscript{[86]}. The first step in a screening is to determine the CFH, CFI and MCP levels using radio-immune-diffusion assay (RIDA) or FACS. FACS analysis of peripheral blood mononuclear cells is useful for detecting MCP mutations. Screening for mutations by determining serum levels or cell-surface expression fails to detect low protein levels in 25\%-75\% of mutations. Genetic analysis is also required.

These level-two investigations provide a genetic assessment of complement genes using direct-fluorescence sequencing and mixed ligation-dependent probe amplification. To rapidly identify the gene involved, genes should be screened based on the frequency of mutation detection (\textit{CFH} 30\%, \textit{MCP} 10\% and \textit{CFI} 2\%-5\%). Furthermore, mutations cluster in certain exons (60\% of \textit{CFH} mutations cluster in complement control protein modules 19 and 20; 90\% of \textit{MCP} mutations in control protein modules 1-4; 60\% of \textit{CFI} mutations in the serine protease domain). By screening these regions first, cost and detection time can be minimized.

Patients awaiting kidney transplantation constitute an exception. \textit{CFI} mutations are less common than \textit{MCP} mutations and, unlike \textit{MCP} mutations, are associated with relapse after kidney transplantation. Thus, in these patients, one possible alternative is to screen for factor I instead of \textit{MCP} after \textit{CFH} to avoid relapse after transplantation. Due to the incomplete penetrance, relatives of patients with aHUS and a recognized complement abnormality should be screened for the same mutation.

### Thrombotic thrombocytopenic purpura

TTP is an uncommon thrombotic microangiopathy that is primarily observed in adults\textsuperscript{[87]}, often with central-nervous-system involvement, a high relapse rate and with a mortality rate of 15\%-20\% also in patients treated by plasma exchange\textsuperscript{[88]}. Due to its potentially similar clinical presentation, a differential diagnosis of HUS D+ and aHUS should be considered. TTP is associated with acquired (or less commonly genetic) ADAMTS13 deficiency\textsuperscript{[89]}.

### Pathophysiology

ADAMTS13 is a disintegrin and metalloprotease that cleaves vWF. vWF is central in hemostasis, because it induces platelets aggregation and thrombus formation on the damaged endothelium. Endothelial cells produce vWF as a large multimer. ADAMTS13 then degrades vWF into progressively smaller circulating products. The deficit is more commonly acquired and caused by anti-ADAMTS13 antibodies\textsuperscript{[90]}. Antibody inhibitors are described in patients treated with ticlopidine\textsuperscript{[91]}. Severe ADAMTS13 deficiency is required to cause TTP and is variably defined as < 5\% or < 10\% of normal protease activity\textsuperscript{[92]}.

### Diagnosis

ADAMTS13 assays do not provide prognostic information; indeed, prospective studies suggest that severe ADAMTS13 deficiency is not found in all patients who may be appropriately diagnosed with TTP-HUS and who may respond to plasma exchange\textsuperscript{[93]}. Inhibitory auto-antibodies identified during the acute episode may be associated with a worse prognosis. Once patients are in remission, severe protease deficiency or the presence of inhibitors is associated with an increased risk of relapse\textsuperscript{[94]}. Congenital TTP occurs due to mutations in \textit{ADAMTS13}\textsuperscript{[95]}. More than 90 such mutations have been described\textsuperscript{[96]}.
neurological or cardiac symptoms are also observed. AHUS is clinically similar to other thrombotic microangiopathies and TTP.

Clinical and differential diagnosis of HUS D+, atypical HUS and TTP

A correct and prompt differential diagnosis is essential for appropriate treatment. In children, but not in adults, the age of onset, family history, and clinical presentation are useful for a correct differential diagnosis; however it is possible to positively identify the HUS subtype. In neonates and in children younger than 6 mo of age, the most probable diagnosis is aHUS due to congenital complement abnormalities, although SPA-HUS may also occur. Congenital TTP (Upshaw-Schulman syndrome) and methylmalonic aciduria should be considered in the differential diagnosis. In children between 6 mo and five years of age, post-diarrheal STEC-HUS predominates, but complement-related HUS is also possible. In adolescent and preadolescent patients, aHUS due to complement abnormalities prevails, primarily due to MCP abnormality and anti-factor H antibodies. Similarly, TTP due to ADAMTS13 auto antibodies is common at these ages.

In adults, diagnosis may be more difficult because adults may also present with secondary atypical HUS and immune TTP, which may be determined or favored by autoimmune diseases. Pregnancy, transplantation and drugs are other common causes of secondary atypical HUS.

A useful flow chart for a correct differential diagnosis is suggested by the consensus document recently published by Campistol et al. In patients with thrombocytopenia and microangiopathic hemolysis presenting neurological symptoms and/or renal involvement and/or gastrointestinal involvement, ADAMTS13 activity and Shiga toxin/STEC test should be evaluated first. If the ADAMTS13 activity is less than 5%, TTP is the most likely diagnosis; if the Shiga toxin/STEC test is positive, STEC-HUS is the most likely diagnosis. If the ADAMTS13 activity is higher than 5% and the STEC test is negative, a differential diagnosis must be distinguished between aHUS and secondary HUS.

Differential Diagnosis Recommendations

In all patients with HUS symptoms, a Shiga toxin/STEC test should be performed. Anomalous E. coli HUS is a possible diagnosis in patients of unusual age or in whom diarrhea is absent.

ADAMTS13 activity should be determined in all patients with aHUS because clinical manifestations and organ involvements in HUS and TTP can overlap. Blood must be collected before plasma infusion or exchange. Plasma ADAMTS13 can now be determined under 24 h by enzyme-linked immuno sorbent assay. Screening for defective cobalamin metabolism is strongly recommend in children with HUS, because mortality from multisystem failure is high in neonates. A prompt diagnosis...
and B12 supplementation can favor recovery. Screening for complement factors should be performed in all patients with hemolytic elevated liver enzymes low platelets (HLLP) syndrome or post-partum or post-transplant HUS. Complement mutations have been described in 36% of women with HLLP syndrome, 86% of cases of post-partum HUS and 29% of transplanted patients with de novo post-transplant HUS.

**Treatment**

The treatments for the various forms of HUS/TTP are described under the same heading because most of treatment approaches are similar for different diseases. Because the prognosis is often severe, prompt supportive treatment may improve the outcome.

**Supportive treatment**

Electrolytes and water-deficit must be replaced, especially in patients with HUS D+. The recent advancements in intensive care and in dialysis treatment have reduced mortality, mainly in children. For children the best option is peritoneal dialysis. Sometimes, especially in the case of therapy-resistant malignant hypertension, bilateral nephrectomy is life saving and can control the spread of micro vascular lesions when the kidneys are the major site of the disease.

**RECOMMENDATIONS FOR SUPPORTIVE THERAPY IN HUS PATIENTS**

Any patient suspected to have HUS should be sent to a specialized nephrology center, or, if necessary, an intensive care unit. Platelet infusions are strongly contra-indicated unless severe hemorrhagic condition is present or a surgical procedure is planned. Platelet infusions may worsen thrombotic microangiopathy (TMA). Central venous vascular access should be placed for dialysis and/or plasma treatment Prophylactic antibiotics should be administered because infections can trigger relapse. In patients with HUS D+, antibiotic therapy is not indicated. In children with SPA-HUS, all blood products should be washed, and plasma infusion should be avoided to prevent administration of additional anti-T-antigen antibodies.

**Plasma therapy**

To treat HUS D+, using plasma exchange or fresh frozen plasma infusions is still debated. Many use such procedures, but their efficacy has not been supported by randomized trials. Anti-platelets agents can be dangerous because of the high risk of bleeding. Platelet infusions are indicated only if massive bleeding occurs or if a surgical procedure is programmed. Red blood-cell transfusions are necessary when hemoglobin levels decrease and anemia symptoms are present. In the case of SPA-HUS, thorough medical and surgical treatment of the invasive pneumococcal infection is essential. Intensive care is often needed because of the multi-organ involvement. In children with SPA-HUS, all blood products should be washed, and plasma infusion should be avoided to prevent the administration of additional anti-T-antigen antibodies. In aHUS, plasma therapy is the first-line treatment, though such treatment is supported by expert opinion more than by randomized clinical trials. Plasma exchange should be performed together with fresh-frozen plasma infusion. Indeed, plasma exchange removes CFH, CFI, CFB and C3 mutated in addition to anti-factor H antibodies, an infusion of frozen fresh plasma normalizes levels of CFH, CFI, CFB and C3. Moreover, plasma exchange associated with plasma infusion avoids the volume overload.

Plasma-therapy efficacy differs according to the mutated factor. Indeed, 63% of patients with factor H mutation have a partial or complete remission with plasma therapy. Stable and complete recovery is obtained in 5% of patients, while 37% progress to death or renal failure. Only 25% of patients with factor I mutations reach partial or complete remission with plasma therapy, while 75% progress to death or renal failure. The prognosis of aHUS due to MCP mutation is not influenced by plasma therapy because MCP is not a circulating protein. Plasma-therapy efficacy is poorly documented in patients with C3, CFB or THBD mutations. On the contrary plasma therapy is strongly recommended, mainly in association with immunosuppressant, in the case of aHUS due to anti-factor H antibodies.

In clinical practice, because biologic data on complement abnormalities or ADAMTS13 activity are not available in short timeframes, expert clinicians suggest that an empiric plasma therapy should be undertaken as soon as possible after presentation.

Plasma therapy should be performed as frequently as possible until a normal platelet count, hemoglobin and LDH have been attained. A lack of improvement with plasma therapy can be ascribed to various causes: HUS due to abnormal cobalamin metabolism or congenital ADAMTS13 deficit or to plasma-therapy resistant complement abnormalities. In such cases, a different treatment should be considered.

**RECOMMENDATIONS FOR PLASMA TREATMENT**

Plasma therapy in patients with HUS D+ could be useful but has not been supported by randomized trials. All patients suspected to have aHUS should first be treated by plasmapheresis and/or frozen-plasma infusions. This “empiric plasma therapy” should be started as soon as possible, after presentation.

Plasma therapy should be performed as frequently as possible, with plasma exchange (PE) at 1.5 plasma volumes per session. When disease activity is controlled by daily PE, the recommended subsequent frequency of PE is five times a week for 2 wk and three times a week for the subsequent 2 wk. The demonstration of MCP mutation allows the withdrawal of plasma therapy. For patients with CFH, CFI, C3 or CFB mutations, the mo-
dality and the interval between sessions must be determined individually. In “plasma-resistant” cases different diagnoses should be suspected, or different treatments should be tried.

**Peculiar consideration for treatment of HUS D+**

The use of antibiotics, sorbents to bind Shiga toxin and monoclonal antibodies against Shiga toxin are worth consideration in the treatment of HUS D+.

Antibiotic treatment in patients with enterohemorrhagic diarrhea or HUS D+ is controversial. In fact, *in vitro* studies have documented that higher toxin quantities are produced by *E. coli* exposed to non-lethal antibiotic concentrations. In particular, antibiotic therapy during the diarrheal phase is discouraged, because such treatment does not protect against evolution to HUS.

To avoid the evolution of enterohemorrhagic diarrhea to HUS, during the diarrheal phase, sorbents to bind and neutralize Shiga toxin have been administered. Research in this field is still ongoing, but to date, the results have been disappointing.

Another option for the future is to treat patients during the diarrheal phase with monoclonal antibodies against Shiga toxin. In December 2005, the United States Food and Drug Administration (FDA) approved orphan drug status for 2 chimerical anti-Stx antibodies. These antibodies neutralize circulating Stx1 and Stx2, and thus have the potential to treat the disease and prevent serious complications. The drug is still in the experimental phase and, the European Medicines Evaluation Agency (EMEA) has also designated these antibodies as orphan drugs for the same indication.

**Immunosuppression**

Immunosuppression is the treatment that is more commonly adopted for acquired TTP. In fact, although 80% of these patients enter remission with plasma therapy, one-third of them have a relapse. Because the vast majority of patients with TTP have an autoimmune disease, immunosuppressive therapy is indicated when the response to plasma therapy is weak or when following relapses.

Many authors recommend steroid therapy. Nevertheless, randomized controlled trials with high dose steroid therapy are lacking and a relationship between steroids and ADAMTS13 deficit or the presence of inhibitors has not been documented.

Rituximab, a monoclonal anti-CD20 antibody has been prospectively evaluated in adults with unresponsive or relapsing TTP. Alternative immunosuppressive therapies to TTP (e.g. vincristine, cyclophosphamide and cyclosporine) are infrequently used, and their efficacy and safety have not been sufficiently documented. Immunosuppressive therapy is also commonly used in patients with aHUS due to factor-H auto-antibodies.

**Renal transplantation**

While renal transplantation can be safely performed in patients with HUS D+, overall, renal transplantation in atypical HUS is associated with approximately 50% of aHUS relapses. The relapse rate differs according to the genetic abnormality. Patients with factor-H or factor I mutations have poor transplant outcomes, with graft loss within two years of transplantation. In contrast, patients with MCP mutations usually have favorable outcomes. In these patients, the missing protein is present on the cells of the transplanted kidney. Nevertheless, relapses are also described in patients with MCP mutations. These relapses may be ascribed either to endothelial microchimerism or to associated mutations of factor H or factor I.

There are few reports of renal-transplant outcomes in patients with C3 or C3B mutations; however, according to these reports, the relapse incidence appears to be high. In addition, a high incidence of HUS recurrence has been described in patients with anti-factor H antibodies; such patients may benefit from treatment with plasma therapy and rituximab if the treatment is initiated immediately before transplantation.

Renal transplantation from a living related donor is strongly contra-indicated. The risk of a familiar genetic mutation is high, independently from the genetic screening. The results of such screening are often biased by: the inadequacy of the screening and the incomplete penetrance of several mutations. In addition to the risk of relapse in the recipient, the development of aHUS in asymptomatic donors has been reported. Several studies have suggested that calcineurin inhibitors, which have endothelial toxicity, should be avoided; however, mTOR inhibitors may also be toxic to the endothelium, through the down-regulation of vascular endothelial growth factor (VEGF). aHUS may recur after renal transplantation; several studies suggest that plasma therapy at the time of recurrence often fails to rescue kidney function and prevent graft loss. Therefore preventive plasma therapy is recommended. Several observations confirm the benefits of preventive plasma therapy started before surgery and maintained intensively during the first months after transplantation.

**RECOMMENDATIONS FOR RENAL TRANSPLANTATION IN PATIENTS WITH HUS**

Renal transplantation is recommended for patients with HUS D+. Renal transplantation is not recommended in patients with factor H or factor I mutations. Patients with MCP mutations, without associated mutations in factor H, factor I, factor B, C3 and without anti-factor H antibodies have a low risk of relapse after transplantation. Patients with factor-B or C3 mutations have a high risk of relapse, though this finding if based on scarce reports. Patients with anti-factor H antibodies should be treated before transplantation to reduce antibody titers. Renal transplant from living related donors is strongly discouraged. Calcineurin based immunosuppression is still considered the best, in the absence of new immunosuppres-
sant agents. Preventive plasma therapy is recommended to avoid aHUS recurrences after transplantation.

**Combined liver-kidney transplantation**

Factor H and factor I are produced by the liver; therefore, combined liver-kidney transplantation appears the best option for patients with mutations in CFH or CFI. The initial outcomes in patients with CFH mutations were disappointing[128]. Nevertheless, favorable outcomes have recently been reported in patients treated with intensive plasma therapy before and during surgery[129,130].

**RECOMMENDATIONS FOR COMBINED LIVER-KIDNEY TRANSPLANTATION**

Combined liver-kidney transplantation should be undertaken in patients with aHUS due to CFH or CFI mutation. Plasma therapy before and during surgery may improve outcomes. Because there are few reports in the literature, all transplantations in patients with aHUS should be recorded in international registries.

**Eculizumab**

Eculizumab is a recombinant, humanized, monoclonal anti-C5 antibody and is a new drug, recently registered by the FDA and the EMEA for the treatment of aHUS. Eculizumab binds specifically to the complement protein C5, halting the complement cascade and inhibiting production of cell-killing protein complexes[131]. Eculizumab, licensed initially for the treatment of paroxysmal nocturnal hemoglobinuria[132], was recently licensed for the treatment of atypical HUS.

All relevant prospective controlled studies[133] have documented the efficacy of eculizumab in the treatment of aHUS. More recently, eculizumab efficacy was also documented in aHUS recurrence after renal transplantation[134]. Overall, these data suggest that long-term eculizumab treatment is highly effective for the prevention and treatment of post-transplant aHUS recurrence and indicate that anti-C5 therapy should be started promptly after a recurrence.

As mentioned above, a complement hyper-activation has recently been suggested to be at the basis of all types of HUS, D+HUS, atypical HUS and TTP. A proof of this concept is provided by the efficacy of eculizumab in treating non atypical HUS. After the report of three children with severe STEC-HUS who fully recovered after receiving eculizumab, eculizumab was used during the STEC-HUS outbreak in Germany in 2011. Many of these patients benefited from treatment, although these data are challenged by the good outcomes obtained from plasma therapy. Whether eculizumab may be a useful adjunct to treating the most severe forms of STEC-HUS must be clarified by definitive reports from the German epidemic and by prospective, randomized, controlled trials. In addition, eculizumab has been used randomly with good results in the treatment of patients with severe TTP and ADAMTS13 deficiency due to high titers of anti-ADAMTS13 antibodies. These patients had not previously responded to treatment with plasma therapy and immunosuppressants[135].

Eculizumab blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria. All patients must be vaccinated against Neisseria meningitides, at least one week before treatment. Maintenance antibiotic prophylaxis is highly recommended because not all serotypes are covered by vaccination. In pediatric patients, vaccination against Haemophilus influenzae and pneumococci is also necessary[84].

It is not still clear how long the eculizumab treatment should be extended. This issue is also relevant because of the high cost of treatment. According to the drug data sheet, the treatment should be chronic. Relapses have been described after drug discontinuation, but some patients can safely withdraw from the drug without relapses. It is currently impossible to predict the most appropriate duration of treatment and which “low-risk” patients will safely discontinue the treatment.

**RECOMMENDATIONS FOR ECULIZUMAB TREATMENT**

Eculizumab is the drug of choice for the treatment of aHUS. Its usefulness in D+HUS and TTP should be clarified by prospective, randomized trials. The success of eculizumab treatment is related to its use immediately after aHUS diagnosis. In pediatric patients in whom plasma therapy could be technically difficult, early eculizumab use is recommended before aHUS diagnosis. Eculizumab is the treatment of choice for aHUS recurrence after transplantation. Severe thrombotic microangiopathy has been observed upon the discontinuation of eculizumab, and monitoring should continue for at least 12 wk after discontinuation. Patients must be vaccinated against Neisseria meningitides before being treated with eculizumab. Antibiotic prophylaxis is recommended during eculizumab treatment.

**New therapies**

Several complement inhibitors are in phase-I or phase-II trials. Several of these drugs attack C5, but, in contrast to eculizumab, they are small molecules that are less immunogenic and have a potential for oral absorption[136]. Some new compounds have C3 as a target. Such compounds could be more effective, but they may also be less safe, having the potential to cause more infections and autoimmune disease. A further possibility is the replacement of endogenous complement regulators with plasma-purified or recombinant CFH.

**HUS OF UNKNOWN ETIOLOGY**

HUS of unknown etiology occurs often in the course of a systemic disease, a physiopathologic condition or after the assumption of drugs. With the development of our knowl-
edge, in many patients, systemic diseases or drugs appear to be the triggering factor in genetically predisposed subjects. Moreover, a recent study found either mutations or CFH polymorphisms in the majority of patients with secondary aHUS. The main clinical conditions that either cause or represent the triggering factor for aHUS are: (1) Infections, with particular reference to human immunodeficiency virus (HIV); (2) Calcineurin inhibitors and transplantation; (3) Pregnancy; (4) Autoimmune diseases; (5) Malignancy, cancer chemotherapy and ionizing radiation; (6) Glomerular disorders; and (7) Drug assumptions.

Infections
HUS is more prevalent in the HIV-positive population and is associated with high mortality. The pathogenesis of HIV-HUS is poorly understood. It is assumed that the virus directly affects the endothelium, thus causing TMA. Another infection that has recently been recognized as a possible cause of aHUS is H1N1 influenza. H1N1 could cause HUS, either favoring bacterial pathogens such as Streptococcus pneumoniae or acting as a trigger in subjects with complement abnormalities.

One study documented a high incidence of urinary tract infections in TTP patients. This study suggests molecular mimicry between antibodies to infectious agents and ADAMTS13 and suggests the need to identify and treat bacterial infections, which could serve as an antigenic stimulus in patients with TTP.

Other important causes of infectious TMA, mainly in post-transplant patients, are viruses as cytomegalovirus (CMV) and parvovirus B19. CMV infection has been described as a cause of HUS after transplantation of different organs. CMV infection and the use of antithymocyte globulin are significant predisposing factors for the development of HUS after bone-marrow transplantation. Parvovirus B19 is most commonly associated with aplastic anemia refractory to erythropoietin. In some cases, thrombotic microangiopathy associated with collapsing glomerulopathies has preceded allograft vasculitis in renal transplantation.

Calcineurin inhibitors and transplantation
HUS occurs after liver, kidney, heart and bone marrow transplantation. Both de novo HUS and recurrent HUS are observed after renal transplantation. In most patients, the causative role of HUS is the use of calcineurin inhibitors that are thought to precipitate aHUS by direct endothelial cell injury. mTOR inhibitors are often used to avoid this complication, but these drugs may also cause aHUS via VEGF inhibition. In the case of hematopoietic cells transplantation, aHUS seems to be related to the conditioning regimen (irradiation) or to infections developing after transplantation. As mentioned above other relevant causes of HUS in the post-transplant setting are infectious diseases.

Pregnancy
Pregnancy-associated TMA accounts for 8%-18% of all causes of TMA. Pregnancy associated TMA may be related to ADAMTS13 deficiency, complement dysregulation or unknown mechanisms. ADAMTS13-deficiency-related TMA occurs mainly during the second and third trimester of pregnancy. This finding may result from the progressive decrease in ADAMTS13 and the parallel increase in vWF antigen during normal pregnancy. The levels reach their lowest point during the second and third trimesters, which may potentiate the inhibitory effect of anti-ADAMTS13 auto antibodies, thus leading to TMA. HELLP syndrome is another disease that occurs more often in the same pregnancy period. HELLP syndrome is considered a TMA-like disorder based on several similarities between HELLP and HUS/TTP. Interestingly, some forms of HELLP syndrome share a common genetic risk factor of complement dysregulation with aHUS. The question of whether HELLP syndrome is a TMA is relevant because if the link between HELLP syndrome and complement dysregulation is confirmed, complement inhibition may represent a treatment for severe HELLP syndrome. Pregnancy-associated TMA may also occur in the post-partum period.

Autoimmune diseases
HUS may be a clinical manifestation of lupus erythematosus, scleroderma and anti-phospholipids syndrome. HUS/TTP has been reported in 8.4% of Systemic Lupus Erythematosus (SLE) patients. The etiology is unclear. Antibodies to ADAMTS13 and the platelet glycoprotein CD36 have been described in patients with SLE and may cause endothelial injury and trigger the release of ultra-large VWF multimers, culminating in TMA.

Several reports have noted the relationship between TMA and the presence of antiphospholipid antibodies. HUS and, less commonly, TTP and HELLP syndrome, may be the presenting manifestation. The existence of TMA in association with APS forces to rule out the catastrophic variant of the syndrome. Patients with previously diagnosed APS may also develop TMA later during the course of the disease.

Malignancy, cancer chemotherapy and ionizing radiation
Disseminated carcinoma has been associated with HUS. In a registry in the United States, 89% of the 85 patients had adenocarcinoma (mainly gastric). In some patients, HUS developed before the beginning of antineoplastic therapy, but almost all patients received mitomycin during chemotherapy. HUS in disseminated carcinoma may be related either to chemotherapy or to ionizing radiation. Infectious diseases occurring during malignancy may also have a role.

Glomerular disorders
In a small number of cases HUS develops superimposed
on glomerular disease. HUS and membranoproliferative glomerulonephritis may coincide\(^\text{[118]}\). Both diseases are associated with alternative-pathway complement activation and in several patients, mutations affecting factor H have been identified.

**Drugs**

More than 50 drugs and other substances have been associated with the development of TTP/HUS, but many case reports are difficult to interpret because there is uncertainty regarding the diagnosis of TTP/HUS and the relationship of drug exposure to the onset of TTP/HUS\(^\text{[119]}\). Moreover, it is difficult to understand whether aHUS is drug-induced or a consequence of the condition for which the drug was administered\(^\text{[120]}\). The drug may also be a trigger in predisposed subjects. Drugs may cause aHUS via two main mechanisms: immune-mediated damage and direct toxicity.

Quinine, which is used in the treatment of malaria and leg cramps, causes immune-mediated aHUS. HUS induced by quinine-dependent auto-antibodies has been reported in adult patients, usually elderly women\(^\text{[121]}\). Symptoms occur as soon as 12 h after the ingestion of quinine by a sensitized patient.

Calcineurin inhibitors may induce aHUS by direct toxicity to the endothelium, mediated by endothelin-1. mTOR inhibitors may induce aHUS by the inhibition of VEGF\(^\text{[122]}\). Among the drugs used to treat malignancy, cisplatin and mitomycin are known to cause aHUS. Mitomycin C is thought to cause aHUS by a direct toxic effect on the endothelium. In patients receiving mitomycin as part of combination chemotherapy, the incidence of aHUS is 4%-15%\(^\text{[123]}\). The use of anti-platelet agents, the thienopyridine derivatives clopidogrel and ticlopidine, is associated with drug-induced TTP. Laboratory studies indicate that most cases involve an antibody to ADAMTS13 metalloprotease; few cases are caused by direct endothelial damage\(^\text{[124]}\).

**CONCLUSION**

Knowledge of HUS is developing exceptionally rapidly, most likely due to several factors.

**Rare disease**

HUS is a rare disease, and not enough attention has been paid to rare diseases in the past. In part because of the difficulty of collecting and studying cohorts of adequate size. Second because the treatment of rare diseases often relies on progress in related fields such as epidemiology, immunology and genetics. Indeed, while the typical diarrhea-associated HUS was described in 1955, substantial progression has been made in our knowledge of atypical HUS over the last decade.

**Role of genetics**

As mentioned above atypical HUS is primarily related to mutations in the genes encoding regulatory proteins of the complement cascade. Over the last decade, substantial advancements have been made in this field. Outstanding researchers in this field recognize that the work is far from being completed. Indeed, every year new aspects are identified, including many mutations (primarily type II); many aspects of gene penetrance and genetic polymorphisms remain unknown.

**Role of antibodies**

The role of antibodies in TTP has been clarified, as well as the role of antibodies anti factor H. The possible role of antibodies against other complement proteins is still unknown, and their role in secondary HUS or TTP has been identified but not yet clarified. Randomized controlled trials are the basis of evidence-based medicine. Such trials are extremely difficult to be undertaken for a rare disease. Only international cooperation may overcome such difficulties. Fortunately, such cooperation is now in progress and has been repeatedly referenced in this work.

**Orphan drugs**

Rare diseases imply also orphan drugs, including for HUS. Even if national and international guidelines have been made for essential therapies, such as plasma therapy, only recently has a new drug, eculizumab, been approved both by the FDA and EMEA, though only for atypical HUS. Very recent studies report the use of this drug in other forms of TMA. Indeed, the complement hyperactivation seems to be the basis of all forms of TMA. The role of eculizumab in TMA treatment, the duration of therapy and the management of this drug are most likely related to the randomized trials that require international cooperation to be implemented. New drugs are on the horizon, but their development is hindered by the previously mentioned difficulties.

New strains of *E. coli* and/or other microbes producing Shiga toxin should be carefully studied in typical or enterohemorrhagic HUS. In addition to *E. coli* O157:H7, several strains have been recognized to be responsible for HUS, including O157:H4 strain that caused the outbreaks in Germany several years ago.

Moreover, some therapeutic aspects of HUS D+ should be better clarified in terms of the role of plasma therapy. In fact, plasma therapy is not recommended as first-line therapy in HUS D+; though good results were observed in the German outbreaks, they were not observed in randomized trials. The monoclonal antibodies against Shiga toxin could represent a new therapy for the future, but to our knowledge, they are still orphan drugs and lack final approval.

After the report of three children with severe STEC-HUS who recovered fully after receiving eculizumab, eculizumab was used during the STEC-HUS outbreak in Germany in 2011. Many of these patients treated with eculizumab benefitted, even if these data are challenged by the good outcomes obtained by plasma therapy. Whether eculizumab may be a useful adjunct in treating the most severe forms of STEC-HUS must be clarified.
by the definitive reports from the German epidemic and by prospective, randomized, controlled trials.

Genetic studies of TTP must be completed, and new mutations (in addition to the 90 already identified) may be described in the future. The role of the antibodies should also be better clarified, as documented by TTP occurring after drug absorption or pregnancy. Immunosuppressive therapy in the treatment of antibody-mediated TTP is well documented, as in transplantation. The role of eculizumab is still debated but eculizumab may be useful in TTP treatment in patients who are resistant to plasma and immunosuppressive therapy.

In atypical HUS, the detection of new complement-related mutations (both type I and type II) in genes encoding regulatory proteins will improve our understanding of the incomplete penetrance of the disease. In addition, the role of the environment and triggering factors will improve our understanding of the occurrence of the disease in adults.

The role of genetics in secondary HUS is essential. The primary lesson in this field comes from a French study of 21 pregnancy-related HUS. Complement abnormalities were found in 18 of the 21 patients. In our opinion, a comprehensive complement assay should be conducted in all cases of secondary HUS. Currently, secondary HUS is of unknown etiology. Many such diseases will soon be understood.

Finally, this paper makes several diagnostic and clinical recommendations. We present the most current data, but the progressive improvement of our knowledge on HUS and related disorders, will likely change our approach to these diseases. We will thus modify these recommendations as necessary.

REFERENCES

1. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R. Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 1955; 85: 905-909 [PMID: 13247004]

2. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, Rizzoni G, Taylor CM, Van de Kar N, Zimmerhackl LB. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006; 70: 423-431 [PMID: 16775594 DOI: 10.1038/skj.5001581]

3. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8: 622-633 [PMID: 22986360 DOI: 10.1038/nrneph.2012.195]

4. Liu J, Hutzler M, Li C, Pechet L. Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS): the new thinking. J Thromb Thrombolysis 2001; 11: 261-272 [PMID: 11577265 DOI: 10.1023/A:1011921225295]

5. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985; 151: 775-782 [PMID: 3886804 DOI: 10.1093/infdis/151.5.775]

6. O’Brien AO, Lively TA, Chen ME, Rothman SW, Formal SB. Escherichia coli O157: H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet 1983; 1: 702 [PMID: 6132054 DOI: 10.1016/S0140-6736(83)91887-6]

7. Peacock E, Jacob VW, Fallone SM. Escherichia coli O157: H7: etiology, clinical features, complications, and treatment. Nephrol Nurs J 2001; 28: 547-550, 553-555; quiz 556-557 [PMID: 12143430]

8. Clarke SC. Diarrhoegenic Escherichia coli--an emerging problem? Diagn Microbiol Infect Dis 2001; 41: 93-98 [PMID: 11750160 DOI: 10.1016/S0732-8893(01)00303-0]

9. Gyles CL. Shiga toxin-producing Escherichia coli: an overview. J Anim Sci 2007; 85: E45-E62 [PMID: 17085726 DOI: 10.2527/jas.2006-50]

10. Centers for Disease Control and Prevention (CDC). Multistate outbreak of Escherichia coli O157: H7 infections associated with eating ground beef—United States, June-July 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 637-639 [PMID: 12186220]

11. Centers for Disease Control and Prevention (CDC). Two multistate outbreaks of Shiga toxin–producing Escherichia coli infections linked to beef from a single slaughter facility—United States, 2008. MMWR Morb Mortal Wkly Rep 2010; 59: 557-560 [PMID: 20467414]

12. Keene WE, Sazie E, Kok J, Rice DH, Hancock DD, Balan VK, Zhao T, Doyle MP. An outbreak of Escherichia coli O157: H7 infections traced to jerky made from deer meat. JAMA 1997; 277: 1229-1231 [PMID: 9103348 DOI: 10.1001/jama.1997.03540390059036]

13. MacDonald DM, Fyfe M, Paccagnella A, Trinidad A, Louie K, Patrick D. Escherichia coli O157: H7 outbreak linked to salami, British Columbia, Canada, 1999. Epidemiol Infect 2004; 132: 283-289 [PMID: 15061503 DOI: 10.1017/S095026880301651]

14. Clark A, Morton S, Wright P, Corkish J, Bolton FJ, Russell J. A community outbreak of Vero cytotoxin producing Escherichia coli O157 infection linked to a small farm dairy. Com Dis Rep CDR Rev 1997; 7: R206-R211 [PMID: 9447786]

15. Guh A, Phan Q, Nelson R, Purviance K, Millaro E, Kinney S, Mohar P, Kasacek W, Carter M. Outbreak of Escherichia coli O157 associated with raw milk, Connecticut, 2008. Clin Infect Dis 2010; 51: 1411-1417 [PMID: 20158911 DOI: 10.1086/657304]

16. From the Centers for Disease Control and Prevention. Outbreak of Escherichia coli O157: H7 infections associated with drinking unpasteurized commercial apple juice—British Columbia, California, Colorado, and Washington, October 1996. JAMA 1996; 276: 1845 [PMID: 8967999 DOI: 10.1001/jama.1996.03540230150039]

17. Cody SH, Glynn MK, Farrar JA, Cairns KL, Griffin PM, Ko bayashi J, Fyfe M, Hoffman R, King AS, Whaiman-than B, Bryant RG, Vugia DJ. An outbreak of Escherichia coli O157: H7 infection from unpasteurized commercial apple juice. Ann Intern Med 1999; 130: 202-209 [PMID: 10049198 DOI: 10.7326/0003-4819-130-3-199902020-00205]

18. Ferguson DD, Scheffel J, Croquista S, Smith K, Moo-Wing A, Anderson E, Knutsen J, De AK, Gershman K. Temporally distinct Escherichia coli O157 outbreaks associated with alfalfa sprouts linked to a common seed source—Colorado and Minnesota, 2003. Epidemiol Infect 2005; 133: 439-447 [PMID: 15962550 DOI: 10.1017/S0950268804003589]

19. Waterborne outbreak of gastroenteritis associated with a contaminated municipal water supply, Walkerton, Ontario, May-June 2000. Can Commun Dis Rep 2000; 26: 170-173 [PMID: 11211701]

20. Mead PS, Griffin PM. Escherichia coli O157: H7. Lancet 1998; 351: 1207-1212 [PMID: 9777854]

21. Blaser MJ. Deconstructing a lethal foodborne epidemic. N Engl J Med 2011; 365: 1835-1836 [PMID: 22029755 DOI: 10.1056/NEJMe110896]

22. Lynn RM, O’Brien SJ, Taylor CM, Adak GK, Chart H, Cheasty T, Coia JE, Gillespie IA, Locking ME, Reilly WJ, WJN | www.wjgnet.com 70 August 6, 2013 | Volume 2 | Issue 3
Smith HR, Waters A, Willshaw GA. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. *Emerg Infect Dis* 2005; 11: 590-596 [PMID: 15829199 DOI: 10.3201/ 1279-6305-40933]

23 Tozzi AE, Caprioli A, Minelli F, Gianviti A, De Petris L, Edefonti A. Shiga-toxin producing *Escherichia coli* infections associated with hemolytic uremic syndrome, Italy 1988-2000. *Emerg Infect Dis* 2003; 9: 106-108 [PMID: 12533290 DOI: 10.3201/eid0901.020266]

24 Johnson S, Mark Taylor C. Hemolytic Uremic Syndrome. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. *Pediatric Nephrology* 2009, (Section 7): 1155-1180 [DOI: 10.1007/978-3-540-76341-3-48]

25 Gerber A, Karch H, Allerberger F, Verweyven HM, Zimmerhackl LB. Clinical course and the role of shiga toxin-producing *Escherichia coli* infection in the hemolytic uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. *J Infect Dis* 2002; 186: 493-500 [PMID: 12195376 DOI: 10.1086/341940]

26 Tschape H, Prager R, Stieczek W, Fruth A, Tietze E, Böhme-G. Verotoxicogenic Citrobacter freundii associated with severe gastroenteritis and cases of haemolytic uraemic syndrome in a nursery school: green butter as the infection source. *Epide- niol Infect 1995; 114: 441-450* [PMID: 7781732 DOI: 10.1017/ S0952680800021518]

27 Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing *Escherichia coli* and haemolytic uraemic syndrome. *Lancet* 2005; 365: 1073-1086 [PMID: 15781103]

28 Wong CS, Jelacic S, Habeih RL, Watkins SL, Tarr PI. The transmission routes. *Opin Pediatr* 2005; 17: 21-29 [PMID: 15829199 DOI: 10.1007/s004670050018]

29 Siegler RL. Spectrum of extrarenal involvement in postdiar- rheal hemolytic-uremic syndrome. *J Pediatr Nephrol* 1994; 12: 511-518 [PMID: 7931868 DOI: 10.1006/snp2-3476(94)70011-X]

30 Sebbag H, Lemeille JL, Moller C, Schmitt M. Colonic stenosis after hemolytic-uremic syndrome. *Eur J Pediatr Surg 1999; 9: 119-120* [PMID: 10342122 DOI: 10.1055/s-2008-107226]

31 Waters AM, Kerecuk L, Luk D, Haq MR, Fitzpatrick MM, Gilbert RD, Inward C, Jones C, Pichon B, Reid C, Slack MP, Van’t Hof W, Dillon MJ, Taylor CM, Tullius K. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. *J Pediatr* 2007; 151: 140-144 [PMID: 17643764 DOI: 10.1016/j.jpeds.2007.03.055]

32 Cochran JB, Panzarino VM, Maes LY, Tecklenburg FW. Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia. *Pediatr Nephrol* 2004; 19: 317-321 [PMID: 14714171 DOI: 10.1007/s00467-003-1382-x]

33 Brandt J, Wong C, Milun S, Roberts J, Smith J, Brewer E, Thiagarajan R, Warady B. Invasive pneumococcal disease and hemolytic uremic syndrome. *Pediatrics* 2002; 110: 371-376 [PMID: 12165993 DOI: 10.1542/peds.110.2.371]

34 Habib R. Pathology of the hemolytic uremic syndrome. In: Kaplan B, Trompeter R, Moake J. Hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. New York: Marcel Dekker, 1992: 315-353

35 Constantinescu AR, Bitzan M, Weiss LS, Christen E, Kaplan BS, Green A, Trachtman H. Non-enteropathogenic hemolytic uremic syndrome: causes and short-term course. *Am J Kidney Dis 2004; 43: 976-982* [PMID: 15168377]

36 Sullivan M, Erlic Z, Hoffmann MM, Arberke K, Patzer L, Budde K, Hoppe B, Zeiler M, Lhotta K, Rybicki LA, Bock A, Berisha G, Neumann HP. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. *Ann Hum Genet 2010; 74: 17-26* [PMID: 20059470 DOI: 10.1111/j.1469-1809.2009.00534.x]

37 Bienaimé F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautès-Fridman C, Villoutreix BO, Blom AM, Frémeaux-Bacchi V. Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. *Kidney Int* 2010; 77: 339-349 [PMID: 20016463 DOI: 10.1038/ki.2009.472]

38 Sellier-Leclerc AL, Frémeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudadour B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C. Differential impact of comple- ment mutations on clinical characteristics in atypical hemolytic uremic syndrome. *Ann Soc Nephrol 2007; 18: 2392-2400* [PMID: 17599974 DOI: 10.1681/ASN.200608811]

39 Noris M, Caprioli J, Bresin E, Mossalì C, Pianetti G, Gamba S, Daina E, Fanelli C, Castelletti F, Sorosina A, Piras D, Don- adelii R, Maranta R, van der Meer J, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic comple- ment abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clin J Am Soc Nephrol 2010; 5: 1844-1859* [PMID: 20595690 DOI: 10.2215/CJN.02210310]

40 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. *N Engl J Med 2009; 361: 1676-1687* [PMID: 19846853 DOI: 10.1056/NEJMra0902814]

41 Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C. Differential impact of comple- ment mutations on clinical characteristics in atypical hemolytic uremic syndrome. *Ann Soc Nephrol 2010; 18: 2392-2400* [PMID: 17599974 DOI: 10.1681/ASN.200608811]

42 Salvadore M et al. Hemolytic uremic syndrome: An update associated with verocytotoxin-producing *Escherichia coli* infections. *Hum Pathol 1988; 19: 1102-1108* [PMID: 3047052 DOI: 10.1016/0046-8177(88)80093-5]

43 Siegler RL. Spectrum of extrarenal involvement in postdiar- rheal hemolytic-uremic syndrome. *J Pediatr Nephrol* 1994; 12: 511-518 [PMID: 7931868 DOI: 10.1006/snp2-3476(94)70011-X]
Salvadori M et al. Hemolytic uremic syndrome: An update

1739-1754 [PMID: 7175439 DOI: 10.1084/jem.156.6.1739]

53 Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein betaTH for cleavage of C3b and C4b in solution. J Exp Med 1977; 146: 257-270 [PMID: 301546 DOI: 10.1084/jem.146.1.257]

54 Richards A, Kavanagh D, Atkinson JP. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states, the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007; 96: 141-177 [PMID: 17981206]

55 Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moultou E, Frémeaux-Bacchi V, Remuzzi G, Norris M, Goodship TH, Atkinson JP. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007; 44: 111-122 [PMID: 16882452]

56 Delaveye M, Norris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrecht D, Zojia C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345-357 [PMID: 19625716 DOI: 10.1056/NEJMoa081079]

57 Schmidt CQ, Herbert AP, Hocking HG, Uhrin D, Barlow PN. Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol 2008; 151: 14-24 [PMID: 18981690 DOI: 10.1111/j.1365-2249.2007.03553.x]

58 Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Blouin J, Vigneau J, Wu YQ, Ricklin D, Lambris JD, Gros P. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 555-563 [PMID: 15906760 DOI: 10.1681/ASN.2004050380]

59 Ilsma J, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007; 110: 1516-1518 [PMID: 17495132 DOI: 10.1182/blood-2007-02-071472]

60 Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan LD, Goodship TH, Marchbank KJ. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010; 115: 379-387 [PMID: 19861685 DOI: 10.1182/blood-2009-05-221549]

61 Lee BH, Kwak SW, Shin JJ, Lee SH, Choi HJ, Kang HG, Ha IS, Lee JS, Dragon-Durey MA, Choi Y, Cheong HI. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res 2009; 66: 336-340 [PMID: 19531976 DOI: 10.1203/ PDR.0b013e3181b1d4da]

62 Norris M, Brosiochi S, Caprioli J, Todeschini M, Bresin E, Portari F, Gamba S, Remuzzi G. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362: 1542-1547 [PMID: 14615110]

63 Frémeaux-Bacchi V, Moultou EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Liorat C, Atkinson JP. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006; 17: 2017-2025 [PMID: 16762990 DOI: 10.1681/ASN.200510051]

64 Nilsson SC, Kalchishkova N, Trouw LA, Frémeaux-Bacchi V, Villoutreix BO, Blom AM. Mutations in complement factor H as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor H. Eur J Immunol 2010; 40: 172-185 [PMID: 19877009 DOI: 10.1002/eji.200939280]

65 Alba-Dominguez M, López-Lera A, Garrido S, Nozal P, González-Granado I, Meler J, Soler-Palacin P, Cámara C, López-Trascasa M. Complement factor I deficiency: a rare immune defect: characterization of new mutations and the first large gene deletion. Orphanet J Rare Dis 2012; 7: 42 [PMID: 22710145 DOI: 10.1186/1757-1152-7-42]
Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Scheiflinger F, Rieger M, Mudde G, Wolf M, Meyers D, Veyradier A. Prognostic value of anti-ADAMTS13 antibody features (lg isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood 2007; 109: 2815-2822 [PMID: 17164349 DOI: 10.1182/blood-2006-02-060664]

Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132: 794-797 [PMID: 10819702]

Mannucci PM, Peyvandi F. TTP and ADAMTS13: When Is Testing Appropriate? Hematology Am Soc Hematol Educ Program 2007: 121-126 [PMID: 18026419 DOI: 10.1182/ashaveducation.2007.1.121]

Vesely SK, George JN, Lammle B, Studt JD, Aliberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 100: 60-68 [PMID: 12637325 DOI: 10.1182/blood-2003-01-0193]

Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, Wu HM. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141: 651-658 [PMID: 18397340 DOI: 10.1111/j.1365-2457.2008.07107.x]

Levy GG, Nichols WC, Lian EC, Foroud T, McClintock NJ, McGee BM, Yang AY, Siemieniak DR, Stark KR, Grillo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494 [PMID: 11586351 DOI: 10.1038/35070008]

Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010; 91: 1-19 [PMID: 20058209 DOI: 10.1007/s12185-009-0476-1]

Norris M, Bresin E, Mele C, Remuzzi G. Atypical Hemolytic-Uremic Syndrome. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors. SourceGeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle, 2006-2013 [PMID: 20301541]

Lerner-Ellis JP, Tirone JC, Pawelek PD, Doré C, Atkinson JL, Watkins D, Morel CF, Fujiwara TM, Moras E, Hosack AR, Dunbar GV, Antonicka H, Forgetta V, Dobson CM, Leclerc D, Gravel RA, Shoubridge EA, Coulton JW, Lepage PW, Rommens JM, Morgan K, Rosenblatt DS. Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Hum Mutat 1996; 7: 253-261 [PMID: 873176 DOI: 10.1002/(SICI)1098-1004(199602)7:2<253::AID-HUMU8>3.0.CO;2-6]

Nogueira C, Aiello CI, Cerase R, Martins E, Caruso U, Moroni I, Rizzo C, Diogo L, Loco E, Kol F, Deodato F, Schiaffino MC, Boenzi S, Darriba O, Barbot C, Sequeira S, Locatelli M, Santorelli FM, Uziel G, Vilarinho L, Dionisi-Vici C. Spectrum of MMACHC mutations in Italian and Portuguese patients with combined methylmalonic aciduria and homocystinuria, cblC type. Mol Genet Metab 2007; 91: 475-480 [PMID: 18164228 DOI: 10.1016/j.ymgme.2007.08.002]

Salvadori M et al. Hemolytic uremic syndrome: An update

Mira JP, Oksenenduler E, Foullin P, Rondoue E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A. Prognostic value of anti-ADAMTS13 antibody features (lg isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood 2007; 109: 2815-2822 [PMID: 17164349 DOI: 10.1182/blood-2006-02-060664]

Koehl B, Boyer O, Biebuyck-Gouqué N, Kossofotoff M, Frémeaux-Bacchi V, Boddaert N, Niaudet P. Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatric Nephrol 2010; 25: 2539-2542 [PMID: 20714753 DOI: 10.1007/s00467-010-0606-y]

Sallier M, Daniel L, Pieracci MD, Jaubert D, Frémeaux-Bacchi V, Berland Y, Burtex S. Myocardial infarction is a
complication of factor H-associated atypical HUS. *Nephrol Dial Transplant* 2010; 25: 2028-2032 [PMID: 20305136 DOI: 10.1093/ndt/gfq1460].

103. *Loirat* C, Girma JP, Desconclois C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. *Pediatr Nephrol* 2009; 24: 19-29 [PMID: 18574602 DOI: 10.1007/s00467-008-0863-5].

104. *Scheiring* J, Rosales A, Zimmerhakl LB. Clinical practice. Today’s understanding of the haemolytic uraemic syndrome. *Eur J Pediatr* 2010; 169: 7-13 [PMID: 19707787 DOI: 10.1007/s00431-009-1039-4].

105. Remuzzi G, Gallusser M, Salvadori M, Rizzioli G, Paris S, Ruggenenti P. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. *Kidney Int* 1996; 49: 282-286 [PMID: 8770981 DOI: 10.1038/ki.1996.41].

106. Ariceta G, Besbas N, Johnson S, Karpan D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhakl LB. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. *Pediatr Nephrol* 2009; 24: 687-696 [PMID: 18802030 DOI: 10.1007/s00467-008-0964-1].

107. Taylor CM, Machin S, Wigmore SJ, Goodship TH. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. *Br J Haematol* 2010; 148: 37-47 [PMID: 19821824 DOI: 10.1111/j.1365-2457.2009.07916.x].

108. Loirat C, Garnier A, Seller-Leclerc AL, Kwon T. Plasmapheresis in atypical hemolytic uremic syndrome. *Semin Thromb Hemost* 2010; 36: 673-681 [PMID: 20865645 DOI: 10.1055/s-0030-1262890].

109. Zimmerhakl LB. E. coli, antibiotics, and the hemolytic-uremic syndrome. *N Engl J Med* 2000; 342: 1990-1991 [PMID: 10874069 DOI: 10.1056/NEJM200006029342621].

110. Garg AX, Suri RS, Barrowman N, Rehan F, Martsell D, Rosas-Arellano MP, Salvadori M, Haynes RB, Clark WF. Long-term renal prognosis of dialysis-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. *JAMA* 2003; 290: 1360-1370 [PMID: 12966129 DOI: 10.1001/jama.290.10.1360].

111. Trachthain H, Cnaan A, Christen E, Gibbs K, Zhao S, Acheson DW, Weiss R, Kaskell FJ, Spitzer A, Hirschman GH. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. *JAMA* 2003; 290: 1337-1344 [PMID: 12966125 DOI: 10.1001/jama.290.10.1337].

112. Sheoran AS, Chapman-Bonofiglio S, Harvey BR, Mukherjee J, Georgiou G, Donohue-Rolfe A, Tzipori S. Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to *Escherichia coli* O157: H7 prevents fatal intoxication and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. *Br J Haematol* 2007; 136: 451-461 [PMID: 17233847 DOI: 10.1111/j.1365-2457.2006.06448.x].

113. Boyer O, Balzano E, Charbit M, Biebuyck-Gougé N, Salomon R, Dragon-Durey MA, Frémeaux-Bacchi V, Niaudet P. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. *Am J Kidney Dis* 2010; 55: 923-927 [PMID: 20202729 DOI: 10.1053/j.ajkd.2009.12.026].

114. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. *Br J Haematol* 2007; 136: 451-461 [PMID: 17233847 DOI: 10.1111/j.1365-2457.2006.06448.x].

115. Bender M, Lequin M, Bensoussan L, Loirat C, Frémeaux-Bacchi V, Legendre C. New insights into postrenal transplantation hemolytic uremic syndrome. *Pediatr Nephrol* 2011; 27: 23-35 [PMID: 21102542 DOI: 10.1007/s00467-010-1555-2].

116. Donné RL, Abbs I, Barany P, Elinder CG, Little M, Conlon P, Goodship TH. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. *Am J Kidney Dis* 2002; 40: E22 [PMID: 12460067 DOI: 10.1053/j.ajkd.2002.36938].

117. Oyen O, Støren EH, Midttvedt K, Bentdal O, Hartmann A, Bergan S, Pfeffer B, Brekke IB. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. *Am J Transplant* 2006; 6: 412-418 [PMID: 16426329 DOI: 10.1111/j.1600-6143.2005.01184.x].

118. Sartelet H, Toupane O, Lorenzato M, Fadel P, Noel LH, Lagnotte E, Birembaut P, Chanard J, Rieu P. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. *Am J Transplant* 2005; 5: 2441-2447 [PMID: 16162193 DOI: 10.1111/j.1600-6143.2005.01047.x].

119. Hirt-Minkowski P, Schaub S, Mayr M, Schifferli JA, Dickenmann M, Frémeaux-Bacchi V, Steiger J. Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? *Nephrol Dial Transplant* 2009; 24: 3548-3551 [PMID: 19633317 DOI: 10.1093/ndt/gfp377].
Salvadori M et al. Hemolytic uremic syndrome: An update

C therapy with special reference to the total dose. Cancer 1985; 55: 47-50 [PMID: 3917353]

Zakarija A, Kwaan HC, Moake JL, Bandarenko N, Pandey DK, McKoy JM, Yarnold PR, Raisch DW, Winters JL, Raisch TJ, Cursio JF, Luu TH, Richen EA, Fisher MJ, Ortel TL, Tallman MS, Zheng XL, Matsumoto M, Fujimura Y, Bennett CL. Ticlopidine and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int 2009; 112: S20-S24 [PMID: 19180126 DOI: 10.1038/ki.2008.613]

P- Reviewer Ardalon M, Joachim J, Pasquale E  S- Editor Qi Y
L- Editor A  E- Editor Lu YJ
